ArticleJournal of hematology & oncology2026
The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.
Serena Pillozzi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.